MonTa Biosciences Announces Investment to Complete the Ongoing Phase I Monotherapy Trial on MBS8, and a Combination Phase IB/IIA Trial with MBS8 and a Currently Approved Oncology Drug.
October 19, 2022
COPENHAGEN, Denmark, October 20, 2022 — MonTa Biosciences, a clinical-stage biotechnology company focused on stimulating [...]